Racing ahead of Merck and Innovent, Junshi declares PhIII success on cancer that won them 'breakthrough' status
Early this month, the FDA handed Junshi Biosciences an agency first: A breakthrough designation for a PD-(L)1 therapy out of China. Now, the Shanghai-based biotech is declaring pivotal success.
Junshi said Tuesday that, in an interim analysis, their lead drug Toripalimab had improved progression free survival for patients with recurrent or metastatic forms of a rare cancer called nasopharyngeal carcinoma. Junshi did not release any numbers, but the 2-year-long Phase III study, comparing chemotherapy and toripalimab to chemo alone, had been set to enroll 280 patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
